Alternate therapy of type 2 diabetes mellitus (T2DM) with nigella (Ranunculaceae)

Journal of Medicinal Plant Research

Volumn 5, Issue 31, 2011, Pages 6885-6889

  Akash, M S H ^a   Rehman, K ^a   Rasool, F ^b   Sethi, A ^c   Abrar, M A ^d   Irshad, A ^e   Abid, A ^e   Murtaza, G ^f  

^a ZHEJIANG UNIVERSITY   (China)

^b UNIVERSITY OF THE PUNJAB   (Pakistan)

^c GC UNIVERSITY   (Pakistan)

^d THE ISLAMIA UNIVERSITY OF BAHAWALPUR   (Pakistan)

^e BAHAUDDIN ZAKARIYA UNIVERSITY   (Pakistan)

^f Tobe Camp University Road Abbottabad   (Pakistan)

Author keywords

Anti diabetic agent; In vitro analysis; In vivo studies

Indexed keywords

HERBACEOUS AGENT; THYMOQUINONE;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLACK CUMIN; CONTROLLED CLINICAL TRIAL (TOPIC); CROSS-SECTIONAL STUDY; DRUG MECHANISM; GLUCONEOGENESIS; IN VITRO STUDY; IN VIVO STUDY; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN;

NIGELLA; NIGELLA SATIVA; RANUNCULACEAE;

EID: 84855870432     PISSN: None     EISSN: 19960875     Source Type: Journal    
DOI: 10.5897/JMPR11.1425     Document Type: Article

References (64)

1. Alarcon-Aguilara FJ, Roman-Ramos R, Perez-Gutierrez S, Aguilar-Contreras A, Contreras-Weber CC, Flores-Saenz JL (1998). Study of the anti-hyperglycemic effect of plants used as antidiabetics. J. Ethnopharmacol., 61: 101-110.
2. Al-Ghambi MS (2001). Anti-inflammatory, analgesic and antipyretic activity of Nigella sativa. J. Ethnopharmacol., 76: 45-48.
3. Ali BH, Blunden G (2003). Pharmacological and Toxicological Properties of Nigella sativa. Phytother. Res., 17: 299-305.
4. Altan MF, Kanter M, Donmez S, Kartal ME, Buyukbas S (2007). Combination therapy of Nigella sativa and human parathyroid hormone on bone mass, biomechanical behavior and structure in streptozotocin-induced diabetic rats. Acta Histochem., 109: 304-314.
5. Alvarsson M, Arayne MS, Sultana N, Mirza AZ, Zuberi MH, Siddiqui FA (2007). In vitro hypoglycemic activity of methanolic extract of some indigenous plants. Pak. J. Pharm. Sci., 20: 261-268.
6. Bamosa AO, Kaatabi H, Lebda FM, Elq AMA, Sultan AA (2010). Effect of Nigella sativa seeds on the glycemic control of patients with type 2 diabetes. Indian J. Physiol. Pharmacol., 54: 344-354.
7. Baynes JW (1991). Role of oxidative stress in development of complications in diabetes. Diabetes, 40: 405-412.
8. Benhaddou AA, Martineau LC, Spoor D, Vuong T, Leduc C, Joly E, Burt A, Meddah B, Settaf A, Amason JT, Prentki M, Haddad PS (2008). Antidiabetic activity of Nigella sativa seed extract in cultured pancreatic cells, skeletal muscle, and adipocytes. Pharm. Biol., 46: 96-104.
9. Benhaddou AA, Martineau LC, Vallerand D, Haddad Y, Afshar A, Settaf A, Haddad PS (2010). Multiple molecular targets underlie the antidiabetic effect of Nigella sativa seed extract in skeletal muscle, adipocyte and liver cells. Diabetes Obes. Metabol., 12: 148-157.
10. Bhatti AU, Berntorp K, Rehman FU (2009). Effect of prophetic medicine Kalonji (Nigella sativa L.) on lipid profile of human beings, an in vivoapproach. W. Appl. Sci. J., 6: 1053-1057.
11. Bloch-Damti A, Bashan N (2005). Proposed mechanisms for the induction of insulin resistance by oxidative stress. Antioxid. Redox Signal, 7: 1553-1567.
12. Bonora E (2007). Antidiabetic medications in overweight/obese patients with type 2 diabetes, drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. Int. J. Clin. Pract, 61(Suppl. 154): 19-28.
13. Cameron NE, Cotter MA, Basso M, Hohman TC (1997). Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetol. 40: 271-281.
14. Datau EA, Wardhana, Surachmanto EE, Pandelaki K, Langi JA Fias (2010). Efficacy of Nigella sativa on serum free testosterone and metabolic disturbances in central obese male. Acta Med. Indones., 42: 130-134.
15. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner RE, Williams K, Stentz FB, Musi N, Reaven PD (2011). Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance. N. Engl. J. Med., 364: 1104-1115.
16. Dinarello CA (2011). Blocking interleukin-1β in acute and chronic autoinflammaotry diseases. J. Intern. Med., 269: 16-28.
17. Donath MY, Halban PA (2004). Decreased beta-cell mass in diabetes, significance, mechanisms and therapeutic implications. Diabetol., 47: 581-589.
18. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA (2008). Islet Inflammation in Type 2 Diabetes, From metabolic stress to therapy. Diabetes Care, 31(Suppl. 2): S161-S164.
19. El-Dakhakhny M, Mady N, Lembert N, Ammon HP (2002). The hypoglycemic effect of Nigella sativa oil is mediated by extra pancreatic actions. Planta Med., 68: 465-466.
20. El-Kadi A, Kandil M (1987). The black seed (Nigella sativa) and immunity, its effect on human T cell subset. Fed. Proc., 46: 1222-1228.
21. El-Zawahrawy M, Al-Zahrra S (1998). Effect of Nigella sativa on blood level and structure of liver and pancreas in adult male albino rats. Al-Azhar Med. J., 27: 479-483.
22. Fararh KM, Atoji Y, Shimizu Y, Shiina T, Nikami H, Takewaki T (2004). Mechanisms of the hypoglycaemic and immunopotentiating effects of Nigella sativa L. oil in streptozotocin-induced diabetic hamsters. Res. Vet. Sci., 77: 123-129.
23. Fararh KM, Atoji Y, Shimizu Y, Takewaki T (2002). Isulinotropic properties of Nigella sativa oil in Streptozotocin plus Nicotinamide diabetic hamster. Res. Vet. Sci., 73: 279-282.
24. Grover JK, Yadav SP (2004). Pharmacological actions and potential uses of Momordica charantia: A review. J. Ethnopharmacol., 93: 123-132.
25. Hanafy MS, Hatem ME (1991). Studies on the antimicrobial activity of Nigella sativa seed (black cumin). J. Ethnopharmacol., 34: 275-278.
26. Holberg MA, Hotamisligil GS (2006). Inflammation and metabolic disorders. Nature, 444: 860-867.
27. Houstis N, Rosen ED, Lander ES (2006). Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature, 440: 944-948.
28. Ilaiyaraja N and Khanum F (2010). Nigella sativa L, A review of therapeutic applications. J. Herb. Med. Toxicol., 4: 1-8.
29. Jakobsen J, Lundbaek K (1976). Neuropathy in experimental diabetes, an animal model. Br. Med. J., 2: 278-279.
30. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G (2006). Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med., 355: 2427-2443.
31. Kaleem M, Kirmani D, Asif M, Ahmed Q, Bano B (2006). Biochemical effects of Nigella sativa L. seeds in diabetic rats. Indian J. Exp. Biol., 44: 745-748.
32. Kanter M (2008). Effects of Nigella sativa and its Major Constituent, Thymoquinone on Sciatic Nerves in Experimental Diabetic Neuropathy. Neurochem. Res. 33: 87-96.
33. Kanter M, Akpolat M, Aktas C (2009). Protective effects of the volatileoil of Nigella sativa seeds on β-cell damage in streptozotocin-induced diabetic rats, a light and electron microscopic study. J. Mol. Hist., 40: 379-385.
34. Kanter M, Coskun O, Budancamanak M (2005A). Hepatoprotective effects of Nigella sativa L. and Urtica dioica L. on lipid peroxidation, antioxidant enzyme systems and liver enzymes in carbon tetrachloride-treated rats. W. J. Gastroenterol., 11: 6684-6688.
35. Kanter M, Coskun O, Korkmaz A, Oter S (2004). Effects of Nigella sativa on oxidative stress and beta-cell damage in streptozotocin-induced diabetic rats. Anat. Rec. A. Discov. Mol. Cell Evol. Biol., 279: 685-691.
36. Kanter M, Coskun O, Uysal H (2006A). The antioxidative and antihistaminic effect of Nigella sativa and its major constituent, thymoquinone on ethanol-induced gastric mucosal damage. Arch. Toxicol., 80: 217-224.
37. Kanter M, Demir H, Karakaya C, Ozbek H (2005B). Gastroprotective activity of Nigella sativa L oil and its constituent, thymoquinone against acute alcohol-induced gastric mucosal injury in rats. W. J. Gastroenterol., 11: 6662-6666.
38. Kanter M, Meral I, Yener Z, Ozbek H, Demir H (2003). Partial regeneration/proliferation of the ß-cells in the islets of Langerhans by Nigella sativa L. in streptozocin-induced diabetic rats. Tohoku J. Exp. Med., 20: 213-219.
39. Kanter M, OCoskun, M Kalayc, S Buyukbas, F Cagavi (2006B). Neuroprotective effects of Nigella sativa on experimental spinal cord injury in rats. Hum. Exp. Toxicol., 25: 127-133.
40. Karachalias N, Babaei-Jadidi R, Ahmed N, Thornalley PJ (2003). Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem. Soc. Trans., 31: 1423-1425.
41. Khader M, Eckl PM, Bresgen N (2007). Effects of aqueous extracts of medicinal plants on MNNG-treated rat hepatocytes in primary cultures. J. Ethanophormacol., 112: 199-202.
42. Luo Y, Kirksaether N, Lager I, Umegaki H, Wang X, Abe R, Roth GS (1998). Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J. Biol. Chem., 273: 3756-3764.
43. Maritim AC, Sanders RA, Watkins JB 3rd (2003). Oxidative stress and antioxidants. A review. J. Biochem. Mol. Toxicol, 17: 24-38.
44. McFarlane SI (2009). Antidiabetic medications and weight gain, implications for the practicing physician. Curr. Diab. Rep., 9: 249-254.
45. Mitri J, Hamdy O (2009). Diabetes medications and body weight. Expert Opin. Drug Saf., 8: 573-584.
46. Mathur ML, Jyoti G, Ruchika S, Kripa RH (2011). Antidiabetic Properties of a Spice Plant Nigella sativa. J. Endocrinol. Metab., Doi,10.4021/jem12e.
47. Otoom SA, Orn T, Al-Safi SA, Kerem ZK, Alkofahi A (2006). The use of medicinal herbs by diabetic Jordanian patients. J. Herb. Pharmacother., 6: 31-41.
48. Paarakh PM (2010). Nigella sativa Linn.- A comprehensive review. Indian J. Nat. Prod. Resourc. 1: 409-429. Akash et al. 6889
49. Pari L, Sankaranarayanan C (2009). Beneficial effects of thymoquinone on hepatic key enzymes in streptozotocin-nicotinamide induced diabetic rats. Life Sci., 85: 830-834.
50. Prasad SK, Kulshreshtha A, Qureshi TN (2009). Antidiabetic activity of some herbal plants in streptozotocin induced diabetic albino rats. Pak. J. Nutr., 8: 551-557.
51. Purnell JQ, Weyer C (2003). Weight effect of current and experimental drugs for diabetes mellitus, from promotion to alleviation of obesity. Treat. Endocrinol., 2: 33-47.
52. Rahimi R, Nikfar S, Larijani B, Abdollahi M (2005). A review on the role of antioxidants in the management of diabetes and its complications. Biomed. Pharmacother., 59: 365-373.
53. Rchid H, Chevassus H, Nmila R, Guiral C, Petit P, Chokaïri M, Sauvaire Y. (2004). Nigella sativa seed extracts enhance glucose-induced insulin release from rat-isolated Langerhans islets. Fundam. Clin. Pharmacol., 18: 525-529.
54. Sachdeva MM, Stoffers DA (2009). Mini-review, Meeting the Demand for Insulin, Molecular Mechanisms of Adaptive Postnatal ß-Cell Mass Expansion. Mol. Endocrinol., 23: 747-758.
55. Salem ML (2005). Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int. Immunopharmacol., 5: 1749-1770.
56. Sankaranarayanan C, Pari L (2011). Thymoquinone ameliorates chemical induced oxidative stress and β-cell damage in experimental hyperglycemic rats. Chem. Biol. Interact., Doi,10.1016/j.cbi.2011.02.029.
57. Sayed M (1980). Traditional medicine in health care. J. Ethnopharmacol., 2: 19-22.
58. Sharma AK, Thomas PK, De-Molina AF (1977). Peripheral nerve fiber size in experimental diabetes. Diabetes, 26: 689-692.
59. Song F, Jia W, Yao Y, Hu Y, Lei L, Lin J, Sun X, Liu L (2007). Oxidative stress, antioxidant status and DNA damage in patients with impaired glucose regulation and newly diagnosed Type 2 diabetes. Clin. Sci. (Lond), 112: 599-606.
60. Tekeoglu I, Dogan A, Ediz L, Budancamanak M, Demirel A. (2007). Effects of Thymoquinone (Volatile Oil of Black Cumin) on Rheumatoid Arthritis in Rat Models. Phytother. Res., 21: 895-897.
61. Wellen KE, Hotamisligil GS (2005). Inflammation, stress, and diabetes. J. Clin. Invest., 115: 1111-1209.
62. Wild S, Roglic G, Green A, Sicree R, King H (2004). Global prevalence of diabetes, estimates for the year 2000 and projections for 2030. Diabetes Care, 27: 1047-1053.
63. Yki-Järvinen H (2004). Thiazolidinediones. N. Engl. J. Med., 351: 1106-1118.
64. Zaoui A, Cherrah Y, Lacaille-Dubois MA, Settaf A, Amarouch H, Hassar M (2000). Diuretic and hypotensive effects of Nigella sativa in the spontaneously hypertensive rat. Therapy, 55: 379-382.